• Enhanced eye disease
    treatment with long-term
    slow release nanogel


    Learn more
  • Cancer targeting with
    nano-particulate dual-drug
    delivery platform


    Learn more
  • Providing dramatically
    improved anti-cancer
    outcomes and compliance


    Learn more
  • Cannabis infusion into
    beverages while retaining
    the flavour & aroma of drinks


    Learn more
  • High resolution contrast
    agent with less toxicity for
    enhanced MRI diagnostics


    Learn more
  • Enhanced eye disease
    treatment with long-term
    slow release nanogel


    Learn more
  • Cancer targeting with
    nano-particulate dual-drug
    delivery platform


    Learn more
  • Providing dramatically
    improved anti-cancer
    outcomes and compliance


    Learn more
  • Cannabis infusion into
    beverages while retaining
    the flavour & aroma of drinks


    Learn more
  • High resolution contrast
    agent with less toxicity for
    enhanced MRI diagnostics


    Learn more

Avantex Biotechnologies Inc.

Avantex Biotechnologies Inc.

A synergistic nanotechnology dual-drug delivery platform for eye care medical treatments, anti-cancer medical therapies, cannabinoid bioavailability, and MRI diagnostics.

Avantex Biotechnologies has developed Acufilic™ – a groundbreaking nanotechnology-based, dual-drug delivery platformthat improves medical therapeutic and treatment outcomes.

Developed by a team of scientific researchers, this new platformenables the co-delivery of drugs to fuse into nanoparticles with targeting and imaging functions– all produced in a streamlined, self-assembly manufacturing process. The particles are small enough to enter tissue and bind to specific targets, resulting in more efficient therapeutic outcomes.

Avantex’s Acufilic™technology allows for lower dosages and lower toxicity with limited side effects. The Acufilic™ nanotechnology provides affordable and efficacious treatments for patients, resulting in better patient compliance and improved outcomes.

In addition, Acufilic™enables cannabinoids to be infused into beverages without impacting the flavour and aroma of the final products. Acufilic™ can enhance the taste and provide long-term release, enabling other ground-breaking cannabis based advanced dosage forms to come to market.

The Avantex Acufilic™ Advantage and Core Nanotechnology
Our core nanotechnology platform features considerable product advantages including:

  • Amphiphilicity
  • Water soluble
  • High drug encapsulation efficiency
  • Excellent biocompatibility and bioavailability
  • Multi-functionalization
  • Controlled release
  • Streamlined manufacturing process

A synergistic nanotechnology dual-drug delivery platform for eye care medical treatments, anti-cancer medical therapies, cannabinoid bioavailability, and MRI diagnostics.

Avantex Biotechnologies has developed Acufilic™ – a groundbreaking nanotechnology-based, dual-drug delivery platformthat improves medical therapeutic and treatment outcomes.

Developed by a team of scientific researchers, this new platformenables the co-delivery of drugs to fuse into nanoparticles with targeting and imaging functions– all produced in a streamlined, self-assembly manufacturing process. The particles are small enough to enter tissue and bind to specific targets, resulting in more efficient therapeutic outcomes.

Avantex’s Acufilic™technology allows for lower dosages and lower toxicity with limited side effects. The Acufilic™ nanotechnology provides affordable and efficacious treatments for patients, resulting in better patient compliance and improved outcomes.

In addition, Acufilic™enables cannabinoids to be infused into beverages without impacting the flavour and aroma of the final products. Acufilic™ can enhance the taste and provide long-term release, enabling other ground-breaking cannabis based advanced dosage forms to come to market.

The Avantex Acufilic™ Advantage and Core Nanotechnology
Our core nanotechnology platform features considerable product advantages including:

  • Amphiphilicity
  • Water soluble
  • High drug encapsulation efficiency
  • Excellent biocompatibility and bioavailability
  • Multi-functionalization
  • Controlled release
  • Streamlined manufacturing process

Experienced Management Team

Avantex Biotechnologies Inc. is managed by a knowledgeable and motivated team of professionals with extensive international experience and a broad range of biotechnology industry skills.

•  Nikita Chou, MBA – President and Director

•  John Gan – Chief Financial Officer and Director

•  Andrew Csinger, B.Eng, PhD – Chief Strategy Officer

•  Ullrich Schade ­– Vice President, Marketing

•  Vlad Budzynski, M.D, PhD. – Biotechnology Advisor

•  Deanmo Liu, Ph.D – Scientific Advisor

•  Dr. Louis Liu, MD, Ph.D – Medical Advisor

•  Dan Cohen – Vice President, Corporate Strategy

Coming Soon!
Coming Soon!
Coming Soon!